1. Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema.
- Author
-
Huber KL, Stino H, Steiner I, Fuchs P, Goldbach F, Mai J, Gerendas BS, Kriechbaum K, Schmidt-Erfurth U, and Pollreisz A
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Aged, Treatment Outcome, Drug Substitution, Vascular Endothelial Growth Factor A antagonists & inhibitors, Follow-Up Studies, Macular Edema drug therapy, Macular Edema physiopathology, Receptors, Vascular Endothelial Growth Factor therapeutic use, Receptors, Vascular Endothelial Growth Factor administration & dosage, Recombinant Fusion Proteins therapeutic use, Recombinant Fusion Proteins administration & dosage, Diabetic Retinopathy drug therapy, Diabetic Retinopathy diagnosis, Diabetic Retinopathy physiopathology, Intravitreal Injections, Visual Acuity physiology, Angiogenesis Inhibitors therapeutic use, Angiogenesis Inhibitors administration & dosage, Tomography, Optical Coherence
- Abstract
Purpose: To assess the anatomic and functional outcomes in eyes with diabetic macular edema (DME) switched from intravitreal aflibercept to faricimab in a real-world setting., Methods: Retrospective, interventional consecutive case series. Patients with DME were switched from aflibercept to faricimab and categorized based on central subfield thickness (CST) 4 weeks after last aflibercept injection into responding DME (rDME, CST reduction >20% or CST ≤ 250 µm) and nonresponding DME (nrDME, CST unchanged or increased). Patients received a loading dose of two monthly faricimab injections followed by a treat-and-extend regimen. Differences in response between rDME and nrDME were analyzed based on injection interval, change in CST, and visual acuity (VA) 12 weeks postswitch., Results: Fifty-two eyes of 40 patients met inclusion criteria (rDME: n = 26, nrDME: n = 26). Baseline and week 12: VA (logMAR) rDME 0.29 ± 0.23 and 0.22 ± 0.28, nrDME 0.42 ± 0.32 and 0.36 ± 0.29; CST (µm) rDME 370 ± 99 and 288 ± 80, nrDME 384 ± 85 and 380 ± 129. After 12 weeks, 54% rDME and 25% nrDME eyes showed a CST decrease of >20% or CST ≤ 250 µm. Forty-six percent rDME and 50% nrDME eyes had a ±20% CST change, 25% of nrDME eyes had a >20% CST increase, and 73% of rDME eyes and 47% of nrDME eyes reached an extended interval of 8 weeks or longer after 12 weeks., Conclusions: Most DME eyes previously responding or not responding to aflibercept experienced a reduction or stabilization of DME after 12 weeks of faricimab treatment. rDME showed a better anatomic response, and treatment intervals could be extended earlier and longer than nrDME.
- Published
- 2024
- Full Text
- View/download PDF